SeaStar Medical Holding (ICU) Current Deferred Revenue (2023 - 2024)
SeaStar Medical Holding's (ICU) quarterly Current Deferred Revenue came in at $550000.0 in Q3 2024, up 450.0% YoY from $100000.0 in Q4 2023, and up 450.0% on a QoQ basis from $100000.0 in Q4 2023.
SeaStar Medical Holding (ICU) Current Deferred Revenue (2023 - 2024) Analysis & Trends
SeaStar Medical Holding (ICU) has 2 years of Current Deferred Revenue data on file, last reported at $550000.0 in Q3 2024.
- Quarterly Current Deferred Revenue rose 450.0% year-over-year to $550000.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $550000.0 (up 450.0% YoY) and the FY2023 annual result came in at $100000.0, changed N/A from the prior year.
- Current Deferred Revenue advanced to $550000.0 in Q3 2024, from $100000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $550000.0 in Q3 2024 to a low of $100000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | SeaStar Medical Holding | 13.68 Mn | 6.68 Mn | 561,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 550,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |